MAQ-001 + ipilimumab

MAQ-001 + ipilimumab is a combination therapy under clinical investigation for the treatment of advanced solid tumors. **MAQ-001** is a novel anti-PD-1 monoclonal antibody engineered to inhibit T cell exhaustion through a mechanism alternative to standard anti-PD-1/PD-L1 blockade, offering a distinct immunomodulatory profile[2]. **Ipilimumab** is a fully human monoclonal antibody targeting CTLA-4, an immune checkpoint receptor, preventing CTLA-4-mediated inhibition of T cell activation and enhancing antitumor immunity[4]. The combination aims to leverage dual checkpoint inhibition—MAQ-001’s alternative anti-PD-1 activity plus ipilimumab’s anti-CTLA-4—potentially generating synergistic immunotherapeutic effects. This combination is being evaluated in a phase 1 clinical trial for dose-finding, safety, and preliminary efficacy in patients with various advanced, refractory solid malignancies[1][2].

Other names

MAQ-001MAQ001MAQ 001ipilimumabYervoy